Nilotinib, for Patients With CML-CP, CML-AP, or CML-BC

Condition:   Chronic Myelogenous Leukemia (CML) Intervention:   Drug: Nilotinib Sponsor:   Novartis Pharmaceuticals Available

Source: ClinicalTrials.gov - August 19, 2020 Category: Research Source Type: clinical trials